Hepatic iNKT cells produce type 2 cytokines and restrain antiviral T cells during acute hepacivirus infection

Autor: Svjetlana Raus, Jarrett Lopez-Scarim, Joshua Luthy, Eva Billerbeck

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

Chronic hepatitis C virus (HCV) infection is a curable disease, but the absence of a vaccine remains a major problem in infection prevention. The lack of small animal models and limited access to human liver tissue impede the study of hepatic antivir

Externí odkaz: https://doaj.org/article/6d70eac81bd24aba984899108fb0335a

Human AdV-20-42-42, a promising novel adenoviral vector for gene therapy and vaccine product development

Autor: Patrick W. F. Hadoke, Hilde M. van der Schaar, Mónika Z. Ballmann, Lars Frängsmyr, Satish Boedhoe, Győző L. Kaján, Niklas Arnberg, Abdelaziz Beqqali, Angelique A. C. Lemckert, Svjetlana Raus, Tibor Papp, Lijo John, Andrew H. Baker, Ruben Engelhart, Jerome Custers, Selina Khan, Chantal van der Zalm, Wilfried A.M. Bakker, Katarina Danskog, Menzo J. E. Havenga

Publikováno v: Journal of Virology
Ballmann, M Z, Raus, S, Engelhart, R, Kaján, G L, Beqqali, A, Hadoke, P W, Van Der Zalm, C, Papp, T, John, L, Khan, S, Boedhoe, S, Danskog, K, Frängsmyr, L, Custers, J, Bakker, W A M, Van Der Schaar, H M, Arnberg, N, Lemckert, A A C, Havenga, M & Baker, A H 2021, ' Human AdV-20-42-42, a promising novel adenoviral vector for gene therapy and vaccine product development ', Journal of Virology . https://doi.org/10.1128/JVI.00387-21

Preexisting immune responses toward adenoviral vectors limit the use of a vector based on particular serotypes and its clinical applicability for gene therapy and/or vaccination. Therefore, there is a significant interest in vectorizing novel adenovi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48497be299d919b9a4152e8036bbfb91
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-189474